|
End-of-day quote
Pakistan S.E.
2026-10-28
|
5-day change | 1st Jan Change | ||
| 315.00 PKR | +0.06% |
|
-0.02% | -19.19% |
Projected Income Statement: GlaxoSmithKline Pakistan Limited
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Net sales 1 | - | 65,901 | 68,813 | 74,577 | 81,779 |
| Change | - | - | 4.42% | 8.38% | 9.66% |
| EBITDA | - | - | - | - | - |
| Change | - | - | - | - | - |
| EBIT | - | - | - | - | - |
| Change | - | - | - | - | - |
| Interest Paid 1 | - | -1,462 | -1,368 | -1,569 | -1,788 |
| Earnings before Tax (EBT) 1 | - | 16,683 | 17,779 | 20,558 | 23,569 |
| Change | - | - | 6.57% | 15.63% | 14.65% |
| Net income 1 | 6,536 | 10,025 | 10,490 | 12,420 | 14,268 |
| Change | - | 53.38% | 4.64% | 18.4% | 14.87% |
| Announcement Date | 3/24/25 | 3/26/26 | - | - | - |
1PKR in Million
Estimates
Forecast Balance Sheet: GlaxoSmithKline Pakistan Limited
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Change | - | - | - | - | - |
| Announcement Date | 3/24/25 | 3/26/26 | - | - | - |
Estimates
Cash Flow Forecast: GlaxoSmithKline Pakistan Limited
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| CAPEX 1 | 1,316 | 1,304 | 1,533 | 1,649 | 2,775 | 2,583 |
| Change | - | -0.93% | 17.6% | 7.56% | 68.3% | -6.94% |
| Free Cash Flow (FCF) 1 | 4,609 | 3,545 | -1,509 | -1,126 | 3,051 | 6,758 |
| Change | - | -23.09% | -142.58% | 25.41% | 371% | 121.49% |
| Announcement Date | 4/6/21 | 4/4/22 | 3/28/23 | 4/1/24 | 4/7/25 | 4/9/26 |
1PKR in Million
Estimates
Forecast Financial Ratios: GlaxoSmithKline Pakistan Limited
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
| EBITDA Margin (%) | - | - | - | - | - | - | - | - | - |
| EBIT Margin (%) | - | - | - | - | - | - | - | - | - |
| EBT Margin (%) | - | - | - | - | - | 25.32% | 25.84% | 27.57% | 28.82% |
| Net margin (%) | - | - | - | - | - | 15.21% | 15.24% | 16.65% | 17.45% |
| FCF margin (%) | - | - | - | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - | - | - | - | - |
Profitability | |||||||||
| ROA | - | - | - | - | - | 20.94% | 20% | 20% | 21% |
| ROE | - | - | - | - | - | 29.77% | 30% | 30% | - |
Financial Health | |||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - | - |
Capital Intensity | |||||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | - | - | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - | - |
Items per share | |||||||||
| Cash flow per share 1 | - | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | 17 | 18.04 | 20.81 | 23 |
| Change | - | - | - | - | - | - | 6.12% | 15.35% | 10.52% |
| Book Value Per Share 1 | - | - | - | - | - | 105.7 | 119.7 | 141.3 | 162.6 |
| Change | - | - | - | - | - | - | 13.2% | 18.05% | 15.07% |
| EPS 1 | - | - | - | - | 20.52 | 31.48 | 33.21 | 39.96 | 44.85 |
| Change | - | - | - | - | - | 53.41% | 5.51% | 20.32% | 12.23% |
| Nbr of stocks (in thousands) | - | - | - | - | 318,467 | 318,467 | 318,467 | 318,467 | 318,467 |
| Announcement Date | - | - | - | - | 3/24/25 | 3/26/26 | - | - | - |
1PKR
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | 9.48x | 7.88x |
| PBR | 2.63x | 2.23x |
| EV / Sales | 1.46x | 1.35x |
| Yield | 5.73% | 6.61% |
EPS & Dividend
Y-o-Y evolution of P/E
Year-on-year evolution of the Yield
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
315.00PKR
Average target price
510.00PKR
Spread / Average Target
+61.90%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- GLAXO Stock
- Financials GlaxoSmithKline Pakistan Limited
Select your edition
All financial news and data tailored to specific country editions
